FDA plans to regulate generative AI
admin The most seismic shift currently underway concerns the national approach to immunization. Following President Trump’s...
Health
Pharmalittle: We’re reading about Medicaid obesity-drug coverage, a Regenxbio gene therapy, and more
The cornerstone of the administration’s pharmaceutical platform was a highly publicized pledge to make high-priced...
Public-sector purgatory, and a union-hospital fight
The scale of the impending crisis was brought into sharp focus by a recent report...
Lady Gaga and her fiancé launch a biotech startup
The FTC’s recent move to challenge Amgen’s patent strategy marks a significant escalation in the...
The Healing Gap: How Retired Doctors and Community Clinics Can Bridge America’s Healthcare Divide
After nearly four decades navigating the complex corridors of clinical medicine, I stepped into retirement...
FDA pauses Regenxbio gene therapy trial again due to safety concernsÂ
The clinical hold specifically impacts the development of RGX-121, an investigational gene therapy designed to...
Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection
The crux of the controversy lies in Capricor’s recent announcement that it intends to use...
Americans bought 12% less soda under new SNAP restrictions, study says
Now, a landmark study has provided the first comprehensive look at the empirical consequences of...
Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more
The approval of Regeneron’s Pasatru (garetosmab) represents the culmination of a thirty-year scientific odyssey. For...
Morning Rounds: ACS Severs Alcohol Ties, FDA Leadership Shifts, and the Evolution of Brain Organoids.
The landscape of modern oncology is shifting rapidly, marked not only by breakthroughs in biotechnology...
